Browsing Tag
Alkeus Pharmaceuticals Inc.
1 post
Tarsus completes Alkeus acquisition as Phase 3 retina strategy takes shape
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, paying $450 million upfront for a Phase 3 Stargardt disease program that could expand a fast-growing eye-care business beyond XDEMVY.